Clinical Trial Update: SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating empagliflozin, an SGLT2 inhibitor, for Fontan circulatory failure in congenital heart disease, with the study not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Heart Disease
• Fontan Circulatory Failure

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Subodh Verma | Conditions: Congenital Heart Disease | Phase 3 | Status: NOT_YET_RECRUITING